What Is Stage 3 Endometriosis and How Serious Is It?

Stage 3 endometriosis, classified as “moderate” under the most widely used scoring system, means a surgeon has found deep endometrial implants on pelvic surfaces, cysts on one or both ovaries (called endometriomas), and filmy or dense adhesions binding organs together. It is serious enough to distort pelvic anatomy, threaten fertility, and require ongoing management, but the relationship between stage and how bad you actually feel is far more complicated than the numbering system suggests.

How the Staging System Works

Endometriosis is scored using the revised American Society for Reproductive Medicine (rASRM) classification, a point-based system applied during surgery. A surgeon tallies points based on the size, depth, and location of endometrial implants and adhesions. Stage 1 (minimal) scores 1 to 5 points, stage 2 (mild) scores 6 to 15, stage 3 (moderate) scores 16 to 40, and stage 4 (severe) scores above 40. The jump from stage 2 to stage 3 typically reflects the presence of ovarian endometriomas and more extensive adhesions, not just scattered surface-level spots.

The rASRM system is the best-known and most widely used classification worldwide, but it has a well-recognized blind spot: it does not account well for deeply infiltrating endometriosis that burrows into structures behind the uterus, such as the bowel wall or the ureters.¹ That means two people with stage 3 scores can have very different disease profiles. One might have a single large ovarian cyst with moderate adhesions. Another might have deeply invasive lesions affecting the bowel that go partially uncaptured by the point system. This limitation matters when you are trying to understand how serious your particular stage 3 diagnosis is.

Why Your Stage Does Not Predict Your Pain

One of the most counterintuitive facts about endometriosis is that stage and pain severity are poorly connected. A person with stage 1 disease can be in debilitating pain, while someone with stage 3 or 4 may have relatively mild symptoms. Research has consistently found no correlation between the rASRM stage and the severity of chronic pelvic pain.² The staging system describes what the disease looks like anatomically, not how it feels.

Why the disconnect? Pain in endometriosis involves far more than the size or number of lesions. Nerve infiltration, central sensitization (where the nervous system amplifies pain signals over time), and the location of implants all play roles that the point-based scoring system cannot capture. A systematic review on pelvic pain syndromes and endometriosis described this as a “profound biological decoupling” between what is visible in the pelvis and what the patient experiences.³ The practical takeaway is that a stage 3 diagnosis does not tell you whether your pain will be manageable or severe, and it should not be used to validate or dismiss your symptoms.

Depression and chronic fatigue follow a similar pattern. A cohort study found that the incidence of depressive symptoms and chronic fatigue was independent from the stage of disease.⁴ In other words, the emotional and psychological weight of endometriosis can hit just as hard at any stage.

How Stage 3 Affects Fertility

Fertility is one of the areas where the stage of endometriosis does seem to matter more directly. Endometriosis disrupts fertility through multiple pathways: it alters the environment around eggs and embryos, damages or blocks the fallopian tubes, and changes the lining of the uterus in ways that can impair implantation.⁵ At stage 3, the presence of ovarian cysts and adhesions compounds these effects. Adhesions can physically tether the ovaries, tubes, and uterus, making it harder for an egg to travel where it needs to go.

When it comes to IVF, higher stages of endometriosis are associated with lower pregnancy rates. One study tracking IVF outcomes found a consistent decline in clinical and ongoing pregnancy rates as the stage of endometriosis increased.⁶ That does not mean IVF cannot work for stage 3 patients, but it does mean success rates tend to be lower compared to earlier stages or to people without endometriosis.

A key question many people face is whether to have surgery before starting IVF. A review of the evidence concluded that there is no strong support for surgical intervention before IVF to improve reproductive outcomes in women with advanced-stage endometriosis or endometriomas, and that IVF could be recommended immediately instead.⁷ This is the kind of decision where your reproductive endocrinologist’s assessment of your specific anatomy matters more than the stage number alone.

The Ovarian Reserve Problem

Endometriomas, the chocolate cysts that are a hallmark of stage 3 and 4 disease, do something that simple staging does not capture: they erode ovarian reserve. Women with endometriomas have lower anti-Müllerian hormone (AMH) levels compared to similarly aged women with other types of benign ovarian cysts or no cysts at all.⁸ AMH is the best blood marker for estimating how many eggs remain. So the cysts themselves are quietly reducing your egg supply over time.

Here is where things get tricky: surgically removing endometriomas also reduces AMH. A prospective study found that the rate of AMH decline one month after cystectomy was roughly double in women who had endometriomas removed compared to women who had other benign cysts removed.⁹ This creates a frustrating double bind: leaving the cyst in place gradually damages reserve, but taking it out causes an immediate drop. The decision depends on your age, whether you want children, the size of the cyst, and whether it is causing pain or growing. There is no universally right call.

Surgical Treatment for Stage 3

Surgery is the most direct way to address the visible disease in stage 3 endometriosis. Laparoscopic excision or ablation of implants, removal of adhesions, and cystectomy of endometriomas are the standard approaches. For endometriotic cysts specifically, excisional cystectomy (stripping the cyst wall away from the ovary) is the preferred method for both pain relief and fertility outcomes.¹⁰

Surgery can be effective for pain. A study of patients with stage 3 and 4 endometriosis who underwent ablative laparoscopic surgery found improvements in pain scores and patient satisfaction after the procedure.¹¹ But surgery alone is rarely the end of the story for moderate or severe disease. Without some form of postoperative suppression, recurrence is common.

Medical and Hormonal Therapies

Hormonal treatments for endometriosis aim to suppress the estrogen-driven cycle that feeds endometrial implants. Newer oral GnRH antagonists have emerged as a treatment option, offering pain reduction with a pill rather than injections.¹² Elagolix, one of the first oral GnRH antagonists approved for endometriosis, demonstrated in two large trials that roughly three-quarters of women on the higher dose met clinical response criteria for period pain at three months, compared to about a fifth of women on placebo. For non-menstrual pelvic pain, response rates were more modest but still statistically significant, and the effects held at six months.¹³

Progestins (such as dienogest and medroxyprogesterone acetate) are commonly prescribed after surgery to delay recurrence. A comparative trial of the two found similar recurrence rates between the medications, though dienogest was associated with smaller cyst sizes if recurrence did occur.¹⁴ One randomized trial for stage 3 and 4 patients found that both hormonal suppression and a structured dietary supplementation regimen after surgery were more effective at reducing non-menstrual pelvic pain than surgery plus placebo alone.¹⁵ The fact that a dietary intervention performed comparably to hormonal therapy in that trial is worth discussing with your doctor, especially if hormonal side effects are a concern for you.

Recurrence After Treatment

Endometriosis is a chronic condition, and recurrence after surgery is one of the most frustrating realities of managing it. Reported recurrence rates vary enormously across studies, ranging from roughly 6% to 67% depending on the criteria used and the follow-up period.¹⁶ That wide spread partly reflects differences in how recurrence is defined: does a return of pain count, or only a surgically confirmed new lesion?

A long-term study with a median of eight years of follow-up after laparoscopic surgery for deeply infiltrating endometriosis provides a more granular picture. The cumulative recurrence rate was about 7% at six years and climbed to roughly 14% by twelve years. Pain recurrence and deep lesion recurrence were each uncommon at just over 1%, while cyst recurrence was higher at about 12%. Being younger at the time of surgery was associated with higher recurrence risk, whereas extended postoperative GnRH agonist therapy and becoming pregnant after surgery were both protective.¹⁷ The protective effect of pregnancy is thought to relate to the prolonged suppression of estrogen-driven growth that occurs during pregnancy and breastfeeding, though pregnancy is obviously not a treatment strategy for everyone.

When Endometriosis Involves Other Organs

Stage 3 endometriosis can involve more than the ovaries and pelvic surfaces. Deeply infiltrating disease can burrow into the bowel wall, the ureters, and the bladder. The gastrointestinal tract is the most common site of extrapelvic endometriosis, with the sigmoid colon affected most often, followed by the rectum, the small intestine, the appendix, and the cecum. Most bowel lesions stay on the outer layer, but deeper ones can narrow the bowel and cause symptoms like cyclical bloating, constipation, or rectal bleeding around your period.¹⁸

Urinary tract involvement is less common but can be more dangerous because it is often silent. Ureteral endometriosis may cause no obvious symptoms while gradually obstructing the ureter, potentially leading to kidney damage if not caught.¹⁸ Deeply infiltrating disease involving these organs can cause hydronephrosis (swelling of the kidney from backed-up urine) and bowel stenosis, sometimes requiring complex surgical reconstruction.¹⁹ This is where the limitations of the rASRM staging system become clinically relevant. Two patients with stage 3 scores can be in very different situations if one has disease confined to the ovaries and the other has a lesion compressing a ureter.

The Cancer Question

People with stage 3 endometriosis sometimes worry about cancer risk, and the evidence warrants honest discussion. Endometriomas carry a roughly two- to three-fold increased risk of transformation into certain ovarian cancer subtypes, specifically clear-cell and endometrioid ovarian cancers.²⁰ A study of 1,000 endometriosis patients found endometriosis-associated ovarian cancer in 2% of cases, with endometrioid carcinoma being the most common subtype. All cancer cases in that study occurred in patients with advanced-stage endometriosis (stage 3 or 4).²¹

Before that statistic alarms you: a two- to three-fold relative increase sounds dramatic, but the baseline risk of ovarian cancer in the general population is low (roughly 1 to 2% lifetime risk). Doubling or tripling a small number still gives you a small number. Still, the association is real, and an integrative review noted that the field has moved from viewing endometriosis as purely benign to recognizing that endometriomas, in particular, are conditions with some potential for malignant transformation.²² This does not mean you need to panic, but it is a reason to maintain regular follow-up, especially for persistent or growing endometriomas.

Quality of Life and the Broader Burden

The seriousness of stage 3 endometriosis extends well beyond the pelvis. A large national prospective cohort study found that women with endometriosis scored significantly worse than women without it across every domain of health-related quality of life, including physical functioning, bodily pain, vitality, social functioning, and mental health.²³ These were not subtle differences. The odds of worse physical health scores were roughly 68% higher in women with endometriosis, and the odds of worse mental health component scores were about 28% higher.

The economic cost is substantial. A study in an Eastern Mediterranean population estimated that the average annual cost per endometriosis patient, including healthcare, missed work, and lost productivity, was about $9,900. The same study found a median diagnostic delay of seven years from when symptoms first appeared to when a diagnosis was made.²⁴ A seven-year delay is not an outlier for endometriosis; similar lag times have been reported globally. That gap means many people have already progressed to moderate or severe disease by the time they get a name for what has been happening to them.

How Stage 3 Is Diagnosed

The rASRM stage can only be definitively assigned during surgery, because the scoring requires direct visualization of implants and adhesions. But imaging increasingly plays a role in mapping disease before anyone operates. Transvaginal ultrasound and MRI have similar diagnostic performance for detecting deeply infiltrating endometriosis of the rectosigmoid and uterosacral ligaments, with both achieving high specificity across pelvic locations. Both modalities are weakest at detecting disease in the rectovaginal septum and strongest for rectosigmoid involvement.²⁵ Endometriomas are usually identifiable on ultrasound with high confidence because of their characteristic “ground glass” appearance, so the ovarian component of stage 3 disease is often detected before surgery even takes place.

The search for a blood test or other non-invasive diagnostic tool continues. Circulating microRNAs have shown some promise as potential biomarkers, but the field is still early. A systematic review concluded that individual microRNAs or panels of them could have value in diagnosis and possibly as future treatment targets, though no test is close to clinical use yet.²⁶ An earlier study attempting to build a diagnostic model from plasma microRNAs achieved acceptable sensitivity but poor specificity in an independent validation, underscoring how far this technology still needs to go.²⁷

Genetic Signals and Why Stage 3 Tends to Run in Families

If you have stage 3 endometriosis and a close relative does too, that is not a coincidence. A large multi-ancestry genome-wide association study including over 60,000 endometriosis cases identified 42 significant genetic regions linked to the disease. The genetic effect sizes were largest for stage 3 and 4 endometriosis, driven particularly by ovarian disease. Several of the identified genes regulate processes in the uterine lining and blood, and some are linked to pain perception and maintenance.²⁸ The overall genetic contribution identified so far explains only about 5% of the variation in who develops endometriosis, which means most of the heritability is still unexplained. But the stronger genetic signal in advanced stages suggests that the biological drivers of moderate and severe disease may be partly distinct from those of minimal disease, not just a later point on the same timeline.